Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	15.6	10.86	6.67
Research & Development	96.78	99.53	56.78
Operating Expenses	112.38	110.39	63.45
Operating Income	-112.38	-110.39	-63.45
Interest & Investment Income	2.3	2.94	2.26
Other Non Operating Income (Expenses)	-0.8	-1.72	0
Pretax Income	-111.14	-109.17	-61.18
Net Income	-111.14	-109.17	-61.18
Net Income to Common	-111.14	-109.17	-61.18
Net Income Growth	-	-	-
Shares Outstanding (Basic)	1	1	1
Shares Outstanding (Diluted)	1	1	1
Shares Change	-	24.39%	-
EPS (Basic)	-116.74	-129.23	-90.10
EPS (Diluted)	-116.74	-129.23	-90.10
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Free Cash Flow	-103.3	-97.69	-51.03
Free Cash Flow Per Share	-108.51	-115.65	-75.14
EBITDA	-112.16	-110.14	-63.21
D&A For EBITDA	0.22	0.25	0.24
EBIT	-112.38	-110.39	-63.45

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 23, 2026

Data Sources Report a data error